Para Ombretta, Caruso Lorenzo, Blasi Eleonora, Pestelli Caterina, Pestelli Giulia, Guidi Stefano, Fedi Giacomo, Giarretta Igor, Maggi Fabrizio, Ciarambino Tiziana, Nozzoli Carlo, Dentali Francesco
Department of Emergency Medicine, Careggi University Hospital, 50134 Florence, Italy.
Department of Medicine and Surgery, Insubria University, 21100 Varese, Italy.
J Clin Med. 2022 May 14;11(10):2770. doi: 10.3390/jcm11102770.
Multi-drug resistant organisms (MDRO) are an emerging health problem with an important impact on clinical outcome in Intensive Care Units (ICUs) and immunocompromised patients. Conversely, the role of MDRO colonization in Internal Medicine is less clear. The objective of our study is to evaluate the clinical impact (namely sepsis development, in-hospital and 30-days mortality, and re-hospitalization) of MDRO colonization in Internal Medicine. : Patients admitted to our Internal Medicine Unit between January 2019 and March 2020 were potentially includible. Outcomes in patients with a positive rectal swab for MDRO (RS+) and in patients without a RS+ were compared. Results of the multivariate analyses were expressed as Odds Ratios (ORs) and the corresponding 95% Confidence Interval (CI). : In a cohort of 2147 patients, 77 patients with RS+ were consecutively identified; 377 patients with a rectal swab negative for MDRO were randomly selected from the same cohort (five for each patient with RS+). At the multivariate analysis, RS+ was associated with an increased risk of sepsis development during hospitalization (OR 4.18; 95% CI, 1.99-8.78) and with death or re-hospitalization at 30 days (OR 4.79; 95% CI, 2.79-8.23), whereas RS+ did not appear to be associated with death during hospitalization or need for ICU transfer. However, larger prospective studies and a cost-benefit analysis are needed to confirm our preliminary findings.
多重耐药菌(MDRO)是一个新出现的健康问题,对重症监护病房(ICU)和免疫功能低下患者的临床结局有重要影响。相反,MDRO定植在内科中的作用尚不清楚。我们研究的目的是评估MDRO定植在内科中的临床影响(即脓毒症发生、住院期间和30天死亡率以及再次住院情况)。2019年1月至2020年3月期间入住我们内科病房的患者有可能被纳入研究。比较了MDRO直肠拭子阳性(RS+)患者和无RS+患者的结局。多变量分析结果以比值比(OR)和相应的95%置信区间(CI)表示。在2147例患者队列中,连续识别出77例RS+患者;从同一队列中随机选择377例MDRO直肠拭子阴性的患者(每例RS+患者对应5例)。在多变量分析中,RS+与住院期间脓毒症发生风险增加相关(OR 4.18;95%CI,1.99 - 8.78),与30天时死亡或再次住院相关(OR 4.79;95%CI,2.79 - 8.23),而RS+似乎与住院期间死亡或转入ICU的需求无关。然而需要更大规模的前瞻性研究和成本效益分析来证实我们的初步发现。